Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Accumulated Depreciation: 2021-2022

Historic Accumulated Depreciation for Autolus Therapeutics (AUTL) over the last 2 years, with Dec 2022 value amounting to $27.5 million.

  • Autolus Therapeutics' Accumulated Depreciation rose 21.68% to $29.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $29.0 million, marking a year-over-year increase of 21.68%. This contributed to the annual value of $27.5 million for FY2022, which is 21.24% up from last year.
  • Per Autolus Therapeutics' latest filing, its Accumulated Depreciation stood at $27.5 million for FY2022, which was up 21.24% from $22.7 million recorded in FY2021.
  • Over the past 5 years, Autolus Therapeutics' Accumulated Depreciation peaked at $27.5 million during FY2022, and registered a low of $22.7 million during FY2021.
  • Moreover, its 2-year median value for Accumulated Depreciation was $25.1 million (2021), whereas its average is $25.1 million.
  • Data for Autolus Therapeutics' Accumulated Depreciation shows a peak YoY rose of 21.24% (in 2022) over the last 5 years.
  • Autolus Therapeutics' Accumulated Depreciation (Yearly) stood at $22.7 million in 2021, then grew by 21.24% to $27.5 million in 2022.